Brevan Howard Capital Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.97M | Buy |
+15,636
| New | +$1.97M | 0.01% | 667 |
|
|
2025
Q1 | – | Sell |
-6,600
| Closed | -$901K | – | 1307 |
|
|
2024
Q4 | $901K | Buy |
6,600
+507
| +8% | +$69.2K | 0.01% | 428 |
|
|
2024
Q3 | $702K | Buy |
6,093
+2,109
| +53% | +$243K | ﹤0.01% | 524 |
|
|
2024
Q2 | $548K | Sell |
3,984
-2,146
| -35% | -$295K | ﹤0.01% | 525 |
|
|
2024
Q1 | $845K | Buy |
6,130
+624
| +11% | +$86.1K | 0.01% | 267 |
|
|
2023
Q4 | $725K | Buy |
5,506
+3,551
| +182% | +$468K | 0.01% | 302 |
|
|
2023
Q3 | $220K | Buy |
+1,955
| New | +$220K | ﹤0.01% | 252 |
|